TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14725512
Drug: IM midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IM midazolam 0.08 mg.kg(‐1) (Group M2)
Study: 9048536
Drug: Inhaled furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled furosemide (30 mg)
Study: 9048536
Drug: Inhaled cromolyn
Normalized name: cromolyn Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled cromolyn (30 mg)
Study: 7864916
Drug: Laser vaporization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser vaporization treatment
Study: 29861245
Drug: Pilates-based mat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates-based mat exercises (twice per week, 60-min per session for 16 weeks)
Study: 24050312
Drug: MEDI-528 (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-528 (30, 100, 300 mg) every 2 weeks for 24 weeks
Study: 24050312
Drug: MEDI-528 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-528 (30 mg, 100 mg, 300 mg)
Study: 16556138
Drug: Etidronate treatment
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etidronate treatment (oral, prior to sleep on dialysis days for 23 months)
Study: 9004050
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of 33-40% in daily dosage
Study: 9004050
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of 60-66% in daily dosage
Study: 28104903
Drug: Traction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traction therapy with the Saunders device
Study: 26025383
Drug: TEAS treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEAS treatment (30 minutes each day for 4 consecutive days during HDBR)
Study: 23925377
Drug: Umbilical cord
Normalized name: Sus Scrofa Umbilical Cord
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbilical cord mesenchymal stem cell (MSC) therapy, administered as three transfusions at 1-month intervals over 12 months.
Study: 23925377
Drug: Saline (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (control group), administered in parallel to six patients.
Study: 21936892
Drug: EGML (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGML (2 g/day)
Study: 21936892
Drug: GCE (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCE (2 g/day)
Study: 16608033
Drug: Lamivudine plus
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine plus thymosin alpha1 therapy postoperatively
Study: 14552498
Drug: Customary Outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customary Outpatient Care (CC)
Study: 10465485
Drug: Lateral closed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral closed wedge high tibial osteotomy using AO/ASIF L-plate (Group B)
Study: 8609324
Drug: Intravenous amiodarone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone, 5 mg/kg body weight in 30 min followed by 1,200 mg over 24 h
Study: 1921738
Drug: Org OD
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org OD 14 (2.5 mg daily for 24 months)
Study: 6311914
Drug: Multiple-dose IFN-alpha
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose IFN-alpha 2 (11.4 X 10(6) IU four times per day for four days)
Study: 6311914
Drug: One daily
Normalized name: One Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: One daily treatment of IFN-alpha 2 (42.8 X 10(6) IU once per day for five days)
Study: 6311914
Drug: Both dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosage regimens of IFN-alpha 2
Study: 3885670
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg prostaglandin E2 (PGE2) vaginal suppositories
Study: 3885670
Drug: Combined method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined method of 3 mg PGE2 vaginal suppositories alternating with intranasal oxytocin
Study: 24139548
Drug: Telemedicine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine treatment at home using a video conference system with monitoring equipment (spirometer, thermometer, pulse oximeter) and 24/7 online access to the hospital.
Study: 24139548
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment at the hospital.
Study: 20722752
Drug: Protease inhibitor-sparing
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor-sparing arm (lopinavir/ritonavir+efavirenz)
Study: 19050084
Drug: 150 microg
Normalized name: Norgestrel 150 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 microg x kg(‐1) morphine
Study: 16550736
Drug: Content of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Content of capsule sprinkled on applesauce (Medikinet retard 20 mg)
Study: 16550736
Drug: Intact capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact capsule (Medikinet retard 20 mg)
Study: 10843243
Drug: Peritubular capillary
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritubular capillary flow in steroid resistant, MesP nephrosis
Study: 8383518
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg rac-atenolol
Study: 2876770
Drug: BCG treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG treatment.
Study: 2876770
Drug: BCG treatment
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG treatment in pneumonectomized patients.
Study: 2876770
Drug: BCG treatment
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG treatment vs placebo in lobectomies.
Study: 29880427
Drug: Dobutamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (5 to 20 µg/kg/min) and Nitroglycerin (0.5 to 3 µg/kg/min)
Study: 29880427
Drug: Milrinone (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (loading dose of 50 µg/kg over 10 minutes, followed by maintenance dose of 0.25 to 0.75 µg/kg/min)
Study: 22622705
Drug: Auditory training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auditory training for 4 weeks, 1 hour a day, 5 days a week using both cochlear implant and hearing aid devices.
Study: 20820984
Drug: Docetaxel 45
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 45 mg/m² with bolus/44-h infusion of 5-Fluorouracil/leucovorin (5-Fu/Lv)
Study: 20820984
Drug: Irinotecan 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 180 mg/m² with bolus/44-h infusion of 5-Fluorouracil/leucovorin (5-Fu/Lv)
Study: 9110111
Drug: Propantheline bromide,
Normalized name: Propantheline Bromide, 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propantheline bromide, 64.3 (+/‐ 21.8) mg/day for 7 days, followed by 30 mg orally before repeat tilt-table testing.
Study: 9110111
Drug: Propantheline bromide
Normalized name: Propantheline Bromide
DrugBank: Propantheline (DB00782)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propantheline bromide treatment
Study: 1514336
Drug: Single-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose spinal anaesthesia with 3 ml of plain 0.5% bupivacaine (SDSA group)
Study: 1514336
Drug: Continuous spinal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous spinal anaesthesia using a 32- or 22-gauge catheter with a bolus of 1.0 ml or 0.5 ml of plain 0.5% bupivacaine followed by an infusion at a rate of 2 ml/h (CSA group)
Study: 1514336
Drug: Single-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose spinal anaesthesia (SDSA group)
Study: 3906163
Drug: Soybean phospholipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean phospholipid (18 g daily for 6 weeks)
Study: 31230119
Drug: Intra-articular hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronic acid injection (3 injections weekly starting immediately after ORIF)
Study: 31230119
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no injection after ORIF)
Study: 22067476
Drug: Exenatide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (5 μg bolus in 30 minutes followed by continuous infusion of 20 μg/24 h for 72 h)
Study: 17614243
Drug: Mandatory treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandatory treatment for repeat DUI offenders
Study: 16925757
Drug: Docetaxel (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (70 mg/m² intravenously on day 2 every 21 days) and estramustine (3 x 280 mg/day oral for 5 consecutive days) with dexamethasone (16 mg total daily dose for 5 days)
Study: 16925757
Drug: Estramustine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estramustine (3 x 140 mg/day oral for 3 consecutive days) with dexamethasone (16 mg total daily dose for 3 days)
Study: 12924097
Drug: Inactivated split
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated split trivalent influenza vaccine (IIV), administered parenterally
Study: 12924097
Drug: Live cold‐adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live cold‐adapted reassortant trivalent influenza vaccine (LIV), administered intranasally
Study: 12924097
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both vaccines
Study: 8777253
Drug: Chemotherapy before
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy before surgery
Study: 30440099
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received no PRP injection)
Study: 30360965
Drug: Erenumab 140
Normalized name: Erenumab 140 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 140 mg (via two 70 mg injections) every 4 weeks for 12 weeks
Study: 27449267
Drug: Modified Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Sequential Oral Sensory Approach (M-SOS)
Study: 24586031
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy - 20 mg omeprazole and 1 g amoxicillin for 5 days, followed by 20 mg omeprazole, 500 mg clarithromycin and 500 mg tinidazole for the successive 5 days
Study: 24586031
Drug: 5 day
Normalized name: Fresh 5 Day Deodorant Pads
DrugBank: Aluminum chlorohydrate (DB11573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 day concomitant therapy - 20 mg omeprazole, 1 g amoxicillin, 500 mg clarithromycin and 500 mg tinidazole for 5 days
Study: 24586031
Drug: 14 day
Normalized name: Ponvory 14 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 day concomitant therapy - 20 mg omeprazole, 1 g amoxicillin, 500 mg clarithromycin and 500 mg tinidazole for 14 days
Study: 24586031
Drug: Hybrid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid therapy - 20 mg omeprazole and 1 g amoxicillin for 7 days, followed by 20 mg omeprazole, 1 g amoxicillin, 500 mg clarithromycin and 500 mg tinidazole for the successive 7 days
Study: 17942471
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (5 or 10 g/day) and rhGH (0, 3, or 5 microg/kg/day) for 16 weeks
Study: 15020610
Drug: Three to
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three to four courses of high-dose cytarabine (HDAC)
Study: 15020610
Drug: One course
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One course of high-dose cytarabine (HDAC) followed by alternative intensive consolidation therapy
Study: 11937116
Drug: Dienogest, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest, 1 mg tablet daily for 16 weeks
Study: 11937116
Drug: Decapeptyl, 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decapeptyl, 3.75 mg IM injection every 4 weeks for 16 weeks
Study: 7038842
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with 5-FU and BCNU
Study: 23716985
Drug: Glucomannan (GNN)
DrugBank: Konjac mannan (DB14963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan (GNN) at a dosage of 2.52 g/d (1 sachet of 1.26 g 2 times a day) for 4 weeks
Study: 23716985
Drug: Placebo (maltodextrin)
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin) at the same dosage for 4 weeks
Study: 21846985
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily gentamicin dosing
Study: 21846985
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily gentamicin dosing
Study: 17926624
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at Hegu (LI 4), Neiguan (PC 6), and Zusanli (ST 36) combined with oral administration of Lidocaine
Study: 17926624
Drug: Lidocaine administration
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine administration only
Study: 15523006
Drug: Serial casting
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial casting combined with botulinum toxin A (Botox) injection
Study: 11720760
Drug: Platin-based combination
Normalized name: platinic chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platin-based combination chemotherapy
Study: 11720760
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent therapy with newer cytotoxic agents
Study: 9246961
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments combined (IUI, DIPI, TI) with superovulation
Study: 29952106
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with fractional radiofrequency microneedling and 5% topical minoxidil
Study: 29952106
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with 5% topical minoxidil
Study: 24905061
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) to Metformin (MET)
Study: 18564781
Drug: 0.1% polyhexanide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% polyhexanide gel (Prontosan Gel)
Study: 12456422
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg plus droperidol 1.25 mg after induction and droperidol 1.25 mg 12 h later (Group 1)
Study: 10605163
Drug: Carboplatin (CBCDA)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (CBCDA) 300 mg/m2 day 1, Vindesine (VDS) 3 mg/m2 days 1 and 5, leucovorin (L) 100 mg/m2, 5‐fluorouracil (5‐FU) 370 mg/m2 for 5 days, and 13‐cis retinoic acid (R) 1 mg/kg, administered between chemotherapy courses.
Study: 1881957
Drug: Sham ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ultrasound using placebo cream (Group 1)
Study: 1881957
Drug: Sham ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ultrasound using trolamine salicylate cream (Group 2)
Study: 1881957
Drug: Ultrasound using
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound using placebo cream (Group 3)
Study: 1881957
Drug: Ultrasound using
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound using trolamine salicylate cream (Group 4)
Study: 6823882
Drug: Sustagen with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustagen with 0 mg/kg MSG
Study: 6823882
Drug: Sustagen with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustagen with 100 mg/kg MSG
Study: 6823882
Drug: Sustagen with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustagen with 150 mg/kg MSG
Study: 6823882
Drug: MSG in
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSG in water (150 mg/kg)
Study: 6823882
Drug: Sustagen with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustagen with MSG (all doses)
Study: 29546309
Drug: Resveratrol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (200 mg) and Curcumin (100 mg)
Study: 25548744
Drug: Candesartan and
Normalized name: candesartan and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan and propranolol combination therapy (26 patients)
Study: 25548744
Drug: Propranolol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol monotherapy (27 patients)
Study: 21908494
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy plus paroxetine
Study: 15093982
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg/daily) for 6 weeks
Study: 28340861
Drug: Aclidinium bromide/formoterol
Normalized name: Aclidinium Bromide/Formoterol Fumarate 400 MCG/1 ACTUATION-12 MCG/1 ACTUATION Inhalation Aerosol Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium bromide/formoterol fumarate (AB/FF) 400/12 μg
Study: 12707658
Drug: Biofeedback rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback rehabilitation training method (30 minutes daily for 10 months)
Study: 1419007
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 3 mg and IM saline
Study: 1419007
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline and IM morphine
Study: 3907678
Drug: Flurbiprofen 400
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 400 mg daily for 48 h followed by 200 mg daily
Study: 3907678
Drug: Phenylbutazone 800
Normalized name: Phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylbutazone 800 mg daily for 48 h followed by 400 mg daily
Study: 28214040
Drug: 7.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 g/d AX (n=16)
Study: 28214040
Drug: 15 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/d AX (n=17)
Study: 26962828
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CA19‐9, CA15‐3, and kallikrein‐12
Study: 22353593
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal polysaccharide vaccine (control)
Study: 21258306
Drug: Hypertonic seawater
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic seawater solution
Study: 21258306
Drug: Isotonic seawater
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic seawater solution
Study: 7645538
Drug: Subcutaneous Epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Epoetin alfa (SC) three times per week
Study: 7645538
Drug: Subcutaneous Epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Epoetin alfa (SC) once per week (n = 20)
Study: 7645538
Drug: Subcutaneous Epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Epoetin alfa (SC) diluted 1:2 with bacteriostatic saline (n = 23)
Study: 7645538
Drug: Subcutaneous Epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Epoetin alfa (SC) three times per week (n = 24)
Study: 2482270
Drug: Spray fixation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray fixation (Vale Smear Fix)
Study: 688892
Drug: Atropine 0.5
Normalized name: homatropine 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.5 mg, hyoscine-N-butylbromide 20 mg, and diazepam 5 mg (Group I)
Study: 688892
Drug: Hyoscine-N-butylbromide 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine-N-butylbromide 20 mg and diazepam 5 mg (Group II)
Study: 688892
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg and glucagon 0.2 mg (Group III)
Study: 688892
Drug: Only diazepam
Normalized name: Product containing only diazepam (medicinal product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only diazepam 5 mg intravenously (Group IV)
Study: 31017657
Drug: Adalimumab 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 0.8 mg/kg (40 mg maximum) every other week
Study: 31017657
Drug: Adalimumab 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 0.4 mg/kg (20 mg maximum) every other week
Study: 31017657
Drug: Methotrexate 0.1-0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 0.1-0.4 mg/kg (25 mg maximum) weekly
Study: 25769363
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (635 nm), treated twice a week for 3 weeks (total of 6 treatments)
Study: 22194126
Drug: Botox (current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox (current formulation)
Study: 16938126
Drug: PZ levels
Normalized name: PZ-128
DrugBank: PZ-128 (DB11839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZ levels below the 5.0 percentile (0.52 microg mL‐1)
Study: 16938126
Drug: PZ levels
Normalized name: PZ-128
DrugBank: PZ-128 (DB11839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZ levels below the 2.5 percentile (0.47 microg mL‐1)
Study: 15491435
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate (75 mg)
Study: 11131270
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker treatment during the study